Effect sizes of BOLD CVR, resting-state signal fluctuations and time delay measures for the assessment of hemodynamic impairment in carotid occlusion patients

Jill B. De Vis a,*, Alex A. Bhogal b, Jeroen Hendrikse b, Esben T. Petersen b,c, Jeroen C.W. Siero b,d

a National Institute of Health (NIH) / National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, USA
b Department of Radiology, University Medical Centre Utrecht, Utrecht, The Netherlands
c Danish Research Centre for Magnetic Resonance, Hvidovre Hospital, Denmark
d Spinoza Centre for Neuroimaging Amsterdam, Amsterdam, the Netherlands

ARTICLE INFO

Keywords:
Magnetic resonance imaging
MRI
Blood oxygen level dependent
BOLD
Brain fMRI
Resting-state fMRI
Cerebrovascular reactivity
Cerebrovascular disease

ABSTRACT

Background and purpose: The BOLD signal amplitude as a response to a hypercapnia stimulus is commonly used to assess cerebrovascular reserve. Despite recent advances, the implementation remains cumbersome and alternative ways to assess hemodynamic impairment are desirable. Resting-state BOLD signal fluctuations (rsBOLD) have been proposed however data on its sensitivity and dependence on baseline venous cerebral blood volume (vCBV) is limited. The primary aim of this study was to compare the effect sizes of resting-state and hypercapnia induced BOLD signal changes in the detection of hemodynamic impairment. The second aim of the study was to assess the dependence of BOLD signal variability on vCBV.

Materials and methods: Fifteen patients with internal carotid artery occlusive disease and 15 matched healthy controls were included in this study. The BOLD signal was derived from a dual-echo gradient-echo echo-planar sequence during hypercapnia (HC) and hyperoxia (HO) gas modulations. BOLD (fractional) amplitude of low frequency fluctuations (f)ALFF was compared to HC-BOLD, BOLD response delays derived from time delay analysis and \( \Delta \)BOLD in response to progressively increasing HC. Effect sizes (i.e. the standard mean difference between patients and controls) were calculated. HO-BOLD was used to estimate vCBV, and its contribution to the variability in rsBOLD signal was evaluated.

Results: The effect sizes of ALFF and fALFF (0.61 and 0.72) were lower than the effect sizes related to hypercapnia-based hemodynamic assessment analysis; 1.62, 1.56 and 0.90 for HC-BOLD, BOLD response delays and \( \Delta \)BOLD in response to progressively increasing HC. A moderate relation was found between (f)ALFF and HC-BOLD in controls (R² of 0.61 and 0.42), but this relation decreased in patients (R² of 0.33 and 0.15). (f)ALFF did not differ between patients and controls whereas HC-BOLD did (p < 0.005). The \( \Delta \)BOLD response to progressively increasing HC was significantly different in between patients and controls for \( \Delta \)EtCO₂ values /C21 mmHg (at +2 mmHg F(1, 18) = 5.85, p = 0.026). Up to 31% and 53% of the variance in the ALFF and HC-BOLD spatial distribution could be explained by HO-BOLD.

Conclusion: ALFF and fALFF demonstrated a moderate effect size to detect hemodynamic impairment whereas the effect size was large for methods employing a hypercapnia-based vascular stress stimulus. Based on our analysis of BOLD signal change as a response to a progressively increasing hypercapnia stimulus we can argue that a hypercapnia stimulus of at least 2 mmHg above baseline EtCO₂ is necessary to evaluate hemodynamic impairment. We also demonstrated that a substantial amount of information imbedded in the rsBOLD and HC-BOLD was explained by HO-BOLD. HO-BOLD can serve as a proxy for vCBV and this thus indicates that one should be careful when adopting these techniques in disease cases with compromised CBV.

* Corresponding author. National Institute of Health (NIH) / National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, USA.
E-mail addresses: jill.devis@nih.gov (J.B. De Vis), a.bhogal@umcutrecht.nl (A.A. Bhogal), j.hendrikse@umcutrecht.nl (J. Hendrikse), esbentp@drcmr.dk (E.T. Petersen), j.c.w.siero@umcutrecht.nl (J.C.W. Siero).

https://doi.org/10.1016/j.neuroimage.2018.06.017
Received 5 March 2018; Received in revised form 1 June 2018; Accepted 5 June 2018
Available online 18 June 2018
1053-8119/Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

The brain maintains stable cerebral blood flow by autoregulation and adapting its vascular reserve (Derdyn et al., 1999). These compensatory responses encompass cerebrovascular reserve capacity (CVR) and are mainly achieved by smooth muscle relaxation or contraction. An impairment in CVR has been associated with an increased risk of cerebrovascular disease (Blaser et al., 2002; Yonas et al., 1993; Kuroda et al., 2004; Markus and Cullinan, 2001), to an increased microbleed load (Conijn et al., 2012) and cortical thinning (Fierstra et al., 2010), and has consequences for patient management (Poublanc et al., 2011). CVR can be assessed by administering a vascular stress agent; either by modulating the arterial partial pressure of carbon dioxide (PaCO2) (Poulin et al., 1996; Mark et al., 2010) or by administering a carbonic anhydrase inhibitor such as acetazolamide (ACZ) via injection. Magnetic resonance imaging (MRI) techniques such as arterial spin labelling (ASL) and blood oxygen level-dependent (BOLD) allow for non-invasive measurements of CVR with high spatial resolution and coverage and adequate temporal resolution. Although, a previous study did show BOLD CVR to be more sensitive to hemodynamic impairment than ASL CVR (De Vis et al., 2015a).

The implementation of CVR mapping using gas manipulations is subjected to several considerations, for instance time pressure constraints, medical ethical concerns, the availability of the gas modulation devices, and importantly the tolerability of the patient group to the vascular stress stimulus. CVR is commonly assessed by looking at the BOLD signal amplitude during hypercapnia, administered using a simple block design, however, also more elaborate stimuli have been explored such as a progressively increasing ramp (Sobczyk et al., 2014; Bhogal et al., 2016; Donahue et al., 2014; Sano et al., 2013).

Recently, BOLD MRI resting-state signal fluctuations (rsBOLD) have been proposed as an alternative means for the assessment of cerebral hemodynamics, i.e. CVR (Golestani et al., 2016; Kannurpatti et al., 2014; Jahanian et al., 2014, 2016). The inspiration of applying rsBOLD techniques for the assessment of hemodynamic impairment was based on results reporting that baseline BOLD signal variation contained physiological signal components such as blood pulsation and respiratory-induced changes in PaCO2 (Biswal et al., 2007; Biswal and Kannurpatti, 2009; Kannurpatti et al., 2008; Tong and Frederick, 2010). Non-neuronal fluctuations in hemodynamic parameters were shown to account for ~30% of the variance in gray matter BOLD signal fluctuations (Frederick et al., 2012), and fluctuations in PaCO2 were shown to have a strong influence, up to ~16% of the variance in significant voxels (Wise et al., 2004), on the rsBOLD signal (Golestani et al., 2016; Wise et al., 2004; Chang and Glover, 2009). Although rsBOLD probes more subtle vascular dynamics compared to a BOLD measure of hypercapnic responses, the results of the first few studies applying rsBOLD MRI for hemodynamic impairment assessment have been encouraging (Golestani et al., 2016; Kannurpatti et al., 2014; Jahanian et al., 2014; Lipp et al., 2015). However, studies evaluating the rsBOLD for hemodynamic impairment assessment in patient populations are scarce (Liu et al., 2017a).

Besides BOLD signal amplitude, also the BOLD signal delay time during hypercapnia can be used to probe cerebral hemodynamics (Christen et al., 2015a). The BOLD delay time is thought to depend both on the arrival of blood, i.e. arterial transit time, and the time it takes the vasculature to respond to the elevated PaCO2, i.e. reaction time. As BOLD delay time assessment provides us with two important measures of cerebrovascular health, the technique has gained increasing attention (Christen et al., 2015b; Cogswell et al., 2017; Liu et al., 2017b; Donahue et al., 2015; Champagne et al., 2017).

The primary aim of this study was to compare the different proposed measures of BOLD-MRI-based hemodynamic assessment. In particular, their utility in the assessment of hemodynamic impairment in patients with carotid occlusion was investigated. In these patients, blood flow through the carotid artery is interrupted. This does not necessarily lead to a perfusion deficit but may result in a dilatory response of some of the remaining brain-feeding arteries resulting in a decreased vascular reserve within that area. For our primary aim, effect sizes of BOLD hemodynamic assessment methods relying on the resting-state signal fluctuations, specifically the BOLD signal amplitude of low-frequency fluctuations (ALFF) (Biswal et al., 1995; Zang et al., 2007; Yang et al., 2007) and the fractional ALFF (fALFF) (Zou et al., 2008), were calculated and compared against BOLD hemodynamic assessment methods relying on a vascular stress stimulus. For the latter, effect sizes of block-design, hypercapnia-based CVR (HC-BOLD) (Donahue et al., 2015), BOLD delay time heterogeneity (Donahue et al., 2015), and BOLD signal change as a response to a progressively increasing hypercapnic stimulus (Bhogal et al., 2016) were evaluated. The second aim of this study was to investigate the contribution of baseline venous CBV (vCBV) to the BOLD signal variability to explore the notion that the BOLD signal changes are partly determined by baseline vCBV as predicted by basic BOLD biophysical models (Davis et al., 1998; Ogawa et al., 1993). This is of importance when attributing BOLD signal amplitude fluctuations solely to neuronal activity or as a proxy for PaCO2-related changes in vascular dynamics. In this assessment, adopting previously-made assumptions,
hyperoxia induced BOLD signal changes (HO-BOLD) were taken as a proxy for the vCBV (Liu et al., 2017b; Bulte et al., 2007).

Materials and methods

Subjects

This study was approved by our local institutional review board under protocol number ‘NL 39070.041.11’ and conformed to the standards set by the latest revision of the declaration of Helsinki. Patients with currently asymptomatic occlusive disease of the internal carotid arteries (ICA) and age-and gender matched healthy controls were included in this study. Fifteen currently asymptomatic (for 9 ± 4 years) patients (14 male/1 female) with unilateral or bilateral (3 subjects) ICA occlusion were included. Of these 15 patients, MR imaging could not be completed in 4 patients; 2 patients suffered from claustrophobia and another 2 experienced anxiety during the hypercapnia challenge. A fifth patient had to be excluded due to excessive motion artefacts. Therefore, only data of 10 of the 15 included subjects could be used for final data analysis and those 10 subjects were matched based on age-and gender to ten included healthy controls. Subjects were defined as healthy if no previous history of cerebrovascular disease or other brain disease was present, and if no structural lesions were seen (conventional MRI) and no evidence of steno-occlusive disease of the brain-feeding arteries was present (MR angiography). Signed informed consent was obtained from all participants in this study. Part of the data obtained in this study has been described earlier (De Vis et al., 2015b).

Study design

In the included subjects, an in-house built dual-echo pseudo-continuous arterial spin labelling (pCASL) sequence was performed under hypercapnic (HC) and hyperoxic (HO) gas modulations. The following maps were generated based on the acquired data; BOLD amplitude of low frequency fluctuations (ALFF) maps (Biswal et al., 1995; Zang et al., 2007; Yang et al., 2007), fractional ALFF (fALFF) maps (Zou et al., 2008), HC- and HO-BOLD maps (in %BOLD and as z-score maps). As well, BOLD delay (PLD): 1550 mm2s−1 was calculated as a delay factor between the respiratory signal and the BOLD signal. Additionally, for the hyperoxic condition, an arterial spin labelling (pCASL) sequence was performed under hyperoxia breathing. The two imaging protocols were performed with the same MR system (Achieva, Philips Medical Systems, Best, the Netherlands). A dual-echo pseudo-continuous arterial spin labelling (pCASL) sequence was performed under hyperoxia breathing (HO-BOLD) and under hypercapnia (HC-BOLD). HC-BOLD data were used to temporally align the breathing data with the BOLD signal.

MR imaging

MR imaging was performed on a Philips 3 Tesla system using a quadrature body coil for transmission and an 8-channel head coil for reception (Achieva, Philips Medical Systems, Best, the Netherlands). A dual-echo pseudo-continuous arterial spin labelling (pCASL) sequence was performed. Scan parameters of the pCASL sequence were as follows: TR/TE1/TE2: 4000/13.79/36.25 ms, label duration: 1650 ms, postlabel delay (PLD): 1550–2185 ms (multi-slice readout resulted in varying PLDs), FOV: 240 × 240 mm2, voxel dimensions: 3 × 3 × 7 mm3, number of slices: 11, slice gap: 1 mm, SENSE factor: 2.3, echo train length: 35, volumes: 280, no background suppression, readout: multi-slice gradient-echo (GE) single-shot echo planar imaging (EPI), total scan duration: 18:30.

Respiratory paradigm

A computer-controlled prospective end-tidal gas targeting system (Respiract™, Thornhill Research Inc., Toronto, Canada) was used to modulate end-tidal carbon dioxide and oxygen partial pressures (EtCO2 and EtO2, respectively) (Slessarev et al., 2007). Gas modulations were applied via a breathing circuit sealed to the subject using transparent dressings (Tegaderm, 3M, St Paul, MN). Sample lines were connected from the breathing circuit to the RespirAct device which samples the partial pressures of CO2 and O2 at a rate of 40Hz. The gas-modulation paradigm was as follows; (1) baseline breathing (160s) after which the EtCO2 was gradually ramped up (75s) to hypercapnia which was maintained at a plateau phase (105s) and followed by baseline breathing (70s), (2) hyperoxia breathing (180s), and (3) a repetition of the first block (i.e. EtCO2 gradually (75s) ramped up from baseline to hypercapnia after which the EtCO2 was kept at a stable hypercapnia level for 105s) and finishing off with a baseline period of 200s. A typical graph of the gas-modulation paradigm of one of the subjects is shown in Fig. 1. The average EtCO2 and EtO2 values which were recorded during baseline, hypercapnia, and hyperoxia breathing are shown in Table 1.

Data-analysis

Preprocessing of the BOLD MR images

To ensure a steady-state of the GE-EPI signal, the first four volumes were discarded. The remaining multi-echo data were combined using a contrast-to-noise weighted approach (Fosser et al., 2006). The multi-echo combined interleaved label and control time series data were subsequently motion corrected using an affine or rigid transformation with six degrees of freedom (FMRIB’s Linear Image Registration Tool – FLIRT, FMRIB’s Software Library - FSL) whereby the mean image was taken as a reference image (Jenkinson et al., 2002; Jenkinson and Smith, 2001), linearly detrended (3dDetrend, software for Analysis and visualization of Functional magnetic NeuroImages, AFNI) (Cox, 1996) and spatially smoothed with a 5mm full-width at half-maximum (FWHM) Gaussian kernel (FMRIB’s SUSAN, FSL) (Smith, 1997). The resulting interleaved label and control volumes were averaged using a sliding window of two volumes to generate BOLD time series data, this resulted in a temporal resolution of 4s. Table 1 shows the mean absolute translational motion and the image temporal noise-to-signal ratio (tSNR = 1/sNR*100%) for both subject groups. Considering the small mean absolute motion (≤ 1mm) for both groups, we do not believe that motion artefacts significantly impacted image quality. The same is true for possible eddy currents effects, which we expect to be minimal due to the nature of the EPI gradients used. Moreover, eddy-current induced image distortions will manifest similarly in all volumes for both subject groups, and will, at worst, represent a systematic bias.

The EtCO2 and EtO2 traces recorded by the RespirAct were resampled to match the TR of the BOLD data (4s). BOLD timeseries from a preliminary gray matter (GM) segmentation (see ‘Generating ROIs’ sections below) was used in a correlation between the resampled EtCO2 trace with the BOLD data. The point of maximum correlation was then used to temporally align the breathing data with the BOLD signal.

Generating HC and HO BOLD maps

Maps of hypercapnia (HC) and hyperoxia (HO) induced BOLD signal changes (%) and z-scores were computed using the normalized (between 0 and 1) shifted EtCO2 and EtO2 traces as regressors in a general linear model (FMRI Expert Analysis Tool - Feat, FSL). The hypercapnia %BOLD data were normalized to each subject’s average ΔEtCO2 or ΔEtO2.

Generating maps of ALFF and fALFF

BOLD data were band-pass filtered (0.01–0.08 Hz) to remove very low-frequency drift and high-frequency physiological noise components such as (aliased) respiratory and cardiac induced fluctuations. ALFF maps were computed as the mean square root of the power spectrum in the 0.01–0.08 Hz frequency band for each voxel during the baseline periods (Zou et al., 2008). Before computing the ALFF index per voxel, the absolute BOLD signal was first normalized by the mean BOLD signal in the brain mask. For computing the fALFF index, the sum of the square root of the power in the 0.01–0.08 Hz frequency range was divided by the sum across the entire 0–0.125 Hz frequency range (Zou et al., 2008). This normalization purportedly suppresses physiological noise contributions
Note that data is shown for subjects who were included in this study. The correspondence in absolute motion and image tNSR between groups was not found to be statistically significant across the entire frequency spectrum.

Generating time delay maps

Time delay information of the BOLD signal was based on the Rapid-TiDe approach (Donahue et al., 2015). The entire dataset was used for this analysis, and the shifted EtCO2 trace was used as probe regressor. This differs from the referred paper where lag time was calculated relative to the mean hemodynamic response. In this study, we chose not to relate the lagtime to the mean cerebral hemodynamic response as this would likely already be affected in carotid occlusion patients and would result in a diminished effect size of the time delay metrics. Per voxel, both the BOLD data and regressor time series were oversampled by a factor of 8 to improve estimation of the cross-correlation function, which was extracted over a -30–100s time range. Per subject, the kurtosis and variance of the time delay distribution (in gray and white matter) was computed as an index for time delay heterogeneity (Donahue et al., 2015).

**BOLD signal change as a response to a progressively increasing stimulus**

To assess the BOLD signal change as a response to a progressively increasing stimulus, the CO2 components of the BOLD signal were isolated from the first stable hypercapnic period by manually selecting the starting and ending points of the progressively increasing CO2 stimulus. The second hypercapnic period was not used in this analysis to avoid confounds relating to the effects of residual O2/CO2 on the BOLD signal response. CVR was expressed as the %BOLD signal change as a function of increases in EtCO2, creating BOLD-CVR curves. For each subject, a sigmoidal response model was fit to the CVR response to generate BOLD-CVR response curves as described in (Bhogal et al., 2014, 2015). Next, BOLD-CVR curves of all subjects were shifted with respect to individual measured baseline EtCO2 values (see methods). This allowed us to express changes in CVR as a function of changes in EtCO2 from baseline, thus, facilitating inter-subject averaging of the BOLD-CVR response to progressive hypercapnia.

**Generating ROIs**

All maps were registered to a 2mm Montreal Neurological Institute 152 (MNI-152) atlas (Mazziotta et al., 2001) using an affine transformation with FSL’s FLIRT (Jenkinson et al., 2002). Gray and white matter ROIs were obtained from the Harvard-Oxford atlases for the whole brain gray matter ROIs and the white matter ROI was eroded by one voxel to avoid partial volume effects with gray matter. Analysis of the HC/HO BOLD maps and of the ALFF/fALFF maps was performed using the whole brain gray matter ROIs. Analysis of the time delay maps and of the BOLD signal change as a response to a progressively increasing stimulus was performed using both the whole brain gray matter and the whole brain white matter ROIs.

**Statistical analysis**

One-sided Student’s t-tests were used to assess the differences
between occlusion patients and controls in terms of ALFF, fALFF, HC-BOLD, HO-BOLD, and kurtosis and variance of time delay distribution.

The HC-BOLD response for progressively increasing EtCO₂ was analyzed using a three-way (2 x 2 x 10) mixed design ANOVA with the within- and between-subject factors of EtCO₂ (10 levels), tissue type (gray and white matter) and group type (patient, healthy control), respectively. As the Mauchly’s test indicated that the assumption of sphericity was violated (χ²(44) = 1735, p < 0.001), we corrected the degrees of freedom using Greenhouse-Geisser estimates of sphericity (ε = 0.18). For all computed measured, standardized effect sizes (i.e. the difference between patients and controls in the mean of a measure, divided by the pooled standard deviation) were computed using Cohen’s d. Statistical analysis was performed using SPSS 23.0 (IBM SPSS Statistics for Windows, Version 23.0. Armonk, NY: IBM Corp.). For all statistical tests, a p-value < 0.05 was considered significant.

Results

Of the 15 patients with currently asymptomatic occlusive ICA disease, MRI could not be performed in 2 patients due to claustrophobia and in 2 patients due to anxiety evoked by hypercapnic breathing. Another one patient was excluded from all following analysis due to bad image quality. The mean age of the remaining 10 patients was 65 (±7, 52–73) year. The mean age of the 10 matched controls was 67 (±5, 60–76) year (Table 1). Of the remaining 10 patients, 3 patients had double-sided occlusion of their carotid arteries.

Results for a patient with a right ICA occlusion is shown in Fig. 2A. In this patient, the hemodynamic impairment is clearly visible by the interhemispheric differences in the HC-BOLD and time delay maps; the affected side shows substantial reduced HC-BOLD (%BOLD and z-value map) and prolonged time delays. For the HO-BOLD, ALFF and fALFF maps the impairment is not apparent. Plots of the BOLD signal response (time delay map) and prolonged time delays. For the HO-BOLD, ALFF and fALFF maps any differences are not that clearly observable. Also, note the reduction in high values in large draining cortical vein areas for the z-value HC- and HO-BOLD maps. Fig. 4 shows boxplots of the group average results for gray matter HC-BOLD, HO-BOLD, ALFF and fALFF for the occlusion patients and healthy controls. Only significant differences were found for HC-BOLD, both for the %BOLD and z-score values, which were reduced for the occlusion patients.

The relationships between ALFF and HC-BOLD and HO-BOLD signal changes are shown in Fig. 5A–B for gray matter of healthy controls. High correlations (Pearson’s correlation coefficient, i.e. the coefficient of determination, R² = 0.61 and 0.31, respectively) are found for the relationship between HC-BOLD and ALFF, and for the relationship between HO-BOLD and ALFF, respectively. This indicates that a substantial portion of the spatial variation in ALFF can be explained by HC/HO-BOLD. Knowing that HO-BOLD may act as a proxy for vCBV, these results imply that 31% of the spatial variation in ALFF may be explained by variation in vCBV. Furthermore, in Fig. 5C we demonstrate that, in healthy controls, 53% of the variation in HC-BOLD is subsequently explained by HO-BOLD. When normalizing the ALFF by total amplitude across all frequencies (fALFF), the variation explained by HC-BOLD reduces to 42% but still 29% of variation may be explained by vCBV (HO-BOLD). Table 2 shows all correlation results for both controls and occlusion patients, and for both ALFF and fALFF. Of importance, the correlation (R²) between HC-BOLD and ALFF/fALFF drops to 0.33 and 0.15 in occlusion patients. As well, of the spatial variation in (f)ALFF a substantial portion (~14%–~31%) may be explained by the vCBV for which the HO-BOLD acts as a proxy.

Significant differences in kurtosis and variance of time delay distribution between occlusion patients and controls in both gray and white matter (see Fig. 6A and 6B). Occlusion patients showed lower time delay kurtosis and higher variance, suggesting a wider range in blood arrival times owing to the ICA occlusion, consistent with the expectation that affected regions will prolonged HC induced BOLD response delays.

The HC-BOLD response to progressive hypercapnia for controls and patients with ICA occlusion is shown in Fig. 7. Global reductions in CVR are observed in individuals with occlusions where the difference in %BOLD, and consequently the effect size, increases for higher levels of EtCO₂. Simple main effect analysis showed that the gray matter HC-BOLD ramp response between patients and controls was significantly different (F(1, 18) = 5.74, p = 0.028). Subsequent post-hoc pairwise comparisons, Bonferroni adjusted, revealed that the HC-BOLD ramp response was significantly different at ΔEtCO₂ values above and including +2 mmHg (at +2 mmHg F(1, 18) = 5.85, p = 0.026, see Fig. 7). No significant difference between patients and controls was found for white matter.
tissue ($F(1, 18) = 2.67, p = 0.077$). The mixed design analysis (three way ANOVA with $\Delta$EtCO$_2$, tissue type and group type as the dependent variables) demonstrated a significant interaction for the HC-BOLD response between group type (patients, controls) and $\Delta$EtCO$_2$ ($F(1.74, 162) = 3.61, p = 0.045$). This means that the difference in %BOLD HC-BOLD between occlusion patients and healthy controls depends on the level of administered EtCO$_2$.

Table 3 shows the computed effect sizes (Cohen’s $d$) for the HC-BOLD (%BOLD and z-value), HO-BOLD (%BOLD and z-value), ALFF, fALFF, time delay kurtosis, time delay variance and BOLD response to a progressive hypercapnia stimulus. Of all considered measures, the HC-BOLD and time delay kurtosis and time delay variance show the largest effect size for hemodynamic impairment (>1.11, i.e. large to very large effect size), closely followed by BOLD response to a progressive hypercapnia stimulus (large effect size of 0.9). The effect sizes of ALFF and fALFF are moderate (<0.712) while the effect size of HO-BOLD is small.

Fig. 3. Group average maps of HC-BOLD (%BOLD/mmHg, and z-value/mmHg), HO-BOLD (%BOLD and z-value), ALFF and fALFF for (A) occlusion patients, and (B) age and gender matched healthy controls. Images are shown in radiological convention and have been flipped where necessary to project the occlusion side on the right hemisphere. Both bilateral and unilateral occlusion patients are grouped in these images, grouped images demonstrating solely unilateral occlusion patients can be found in Supplemental Fig. 1. Differences in HC-BOLD between patients and controls are most apparent. For both the %BOLD as the z-value measure; note the reduction in high HC-BOLD values in large draining vein areas for the z-value HC- and HO-BOLD maps.

Fig. 4. Box plots showing the results for gray matter between occlusion patients and age and gender matched healthy controls for (A) HC-BOLD (%BOLD/mmHg), (B), HC-BOLD (z-value/mmHg), (C) HO-BOLD (%BOLD), (D) HO-BOLD (z-value), (E) ALFF, and (F) fALFF. Occlusion patients showed reduced HC-BOLD (both %BOLD/mmHg as z-value/mmHg) compared to control subjects. No apparent differences were found for the HO-BOLD, ALFF and fALFF measures. ** and * denote significant differences for $P < 0.005$ and $P < 0.05$ respectively for a one-sided Student’s t-test.
hypercapnia-assessed hemodynamic impairment was found. ALFF did

could be explained by the HO-BOLD spatial distribution, which was

impairment. Up to 31% of the variance in the ALFF spatial distribution

fl

¼

fALFF

percapnia, HO

¼

the spatial variation in HC-BOLD and (f)ALFF a substantial portion (~31%) can be explained by the baseline venous CBV for which the

HO-BOLD acts as a proxy. HC

– 2 mmHg above baseline EtCO2 is necessary to evaluate hemodynamic

response were found only when the CO2 stimulus reached 2 mmHg above

regarded a proxy for baseline venous CBV. These findings confirm that a substantial amount of the information imbedded in the rsBOLD signal, and the HC-BOLD signal (53% of the spatial variation), is strongly

weighted by the baseline cerebral venous blood volume (vCBV).

The basis for investigating rsBOLD as a means to evaluate cerebral

hemodynamics was established when rsBOLD signals were shown to

have a relationship with EtCO2 (Wise et al., 2004; Chang and Glover,

2009). This finding lead to the presumption that breathing-related

changes in arterial CO2 concentration pose small vasodilatory chal-

lenges, which result in concomitant changes in arterial CBV. However, the relationship between rsBOLD signal and arterial CBV may be confounded by respiratory-related CO2 changes in arterial blood (Mavros et al., 2012).

Furthermore, Liu et al. found a relationship between BOLD signal

fluctuations in the frequency range of 0.02–0.04 Hz and variations in EtCO2 (Liu et al., 2017a), and results from their study showed a reasonable spatial agreement between rsBOLD and HC-BOLD maps (r = 0.71, i.e. R2 = 0.50) (Liu et al., 2017a). The previous reports were supported by our control subjects, where a similar relationship between rsBOLD amplitude of low frequency fluctuations (ALFF) and HC-BOLD was found. However, this relation was attenuated in occlusion patients (from an R2 of 0.61 in controls to 0.33 in patients). The lower agreement found in our patient data as compared to the data of Liu et al. derived from patients with cerebrovascular disease may have been caused by differences in investigated BOLD frequency ranges (Liu et al., 2017a). In our data, we did not detect any significant differences in (f)ALFF between occlusion patients and controls, and this was reflected in a moderate effect size (0.61 for ALFF and 0.72 for fALFF) of rsBOLD MRI to detect hemodynamic impairment.

Compared with the rsBOLD data, the effect size for HC-BOLD was substantially higher compared to the rsBOLD results. Our results regarding the BOLD response to progressive hypercapnia may help to explain this finding. In this analysis, significant differences in the GM response were found only when the CO2 stimulus reached 2 mmHg above resting values. Breathing related fluctuations in EtCO2 values during

Discussion

In this study, different hemodynamic BOLD MRI measures were compared in patients with cerebrovascular disease and healthy controls. In particular, their effect sizes in determining hemodynamic impairment were evaluated. Comparable to earlier studies, a moderate relation between slow fluctuating BOLD signal, i.e. ALFF, and hypercapnia-assessed hemodynamic impairment was found. ALFF did not significantly differ in between patients and controls, and ALFF only demonstrated a moderate effect size to detect hemodynamic impairment. This contrasted with the large effect size seen using hypercapnia-based hemodynamic assessment methods. In addition, based on our analysis of BOLD signal change as a response to a progressively increasing hypercapnia stimulus we can argue that a hypercapnia stimulus at least 2 mmHg above baseline EtCO2 is necessary to evaluate hemodynamic impairment. Up to 31% of the variance in the ALFF spatial distribution could be explained by the HO-BOLD spatial distribution, which was

Table 2

Coefficient of determination R2 of HC- and HO-BOLD versus baseline BOLD fluctuations ALFF and fALFF obtained by Pearson correlation.>

| Study group | HC-BOLD vs. ALFF | HO-BOLD vs. ALFF | HC-BOLD vs. HO-BOLD | HC-BOLD vs. fALFF | HO-BOLD vs. fALFF |
|-------------|------------------|------------------|---------------------|------------------|------------------|
| controls    | 0.61             | 0.31             | 0.53                | 0.42             | 0.29             |
| occlusion patients | 0.33            | 0.23             | 0.37                | 0.15             | 0.14             |

Coefficient of determination R2 of HC and HO-BOLD versus baseline BOLD fluctuations ALFF and fALFF in gray matter obtained by Pearson correlation. Of the spatial variation in HC-BOLD and (f)ALFF a substantial portion (~14%–~31% for occlusion patients and healthy controls respectively) can be explained by the baseline venous CBV for which the HO-BOLD acts as a proxy. HC = hypercapnia, HO = hyperoxia, ALFF = amplitude of low-frequency fluctuations, fALFF = fractional amplitude of low-frequency fluctuations, BOLD = blood oxygenation level-dependent.

Fig. 5. For healthy controls, scatter plots of (A) HC-BOLD versus baseline low-frequency fluctuations ALFF, (B) HO-BOLD versus ALFF, and (C) HC-BOLD versus HO-BOLD. The Pearson correlation coefficient, i.e. coefficient of determination (R (Blaser et al., 2002)) are depicted in the bottom-right corners. High correlations are found for all three measures. Of the spatial variation in HC-BOLD and ALFF a substantial portion (~31%) can be explained by the baseline venous CBV for which the HO-BOLD acts as a proxy. Data points are from gray matter regions.

Table 2

Coefficient of determination R2 of HC- and HO-BOLD versus baseline BOLD fluctuations ALFF and fALFF obtained by Pearson correlation.>

| Study group | HC-BOLD vs. ALFF | HO-BOLD vs. ALFF | HC-BOLD vs. HO-BOLD | HC-BOLD vs. fALFF | HO-BOLD vs. fALFF |
|-------------|------------------|------------------|---------------------|------------------|------------------|
| controls    | 0.61             | 0.31             | 0.53                | 0.42             | 0.29             |
| occlusion patients | 0.33            | 0.23             | 0.37                | 0.15             | 0.14             |

Coefficient of determination R2 of HC and HO-BOLD versus baseline BOLD fluctuations ALFF and fALFF in gray matter obtained by Pearson correlation. Of the spatial variation in HC-BOLD and (f)ALFF a substantial portion (~14%–~31% for occlusion patients and healthy controls respectively) can be explained by the baseline venous CBV for which the HO-BOLD acts as a proxy. HC = hypercapnia, HO = hyperoxia, ALFF = amplitude of low-frequency fluctuations, fALFF = fractional amplitude of low-frequency fluctuations, BOLD = blood oxygenation level-dependent.

Discussion

In this study, different hemodynamic BOLD MRI measures were compared in patients with cerebrovascular disease and healthy controls. In particular, their effect sizes in determining hemodynamic impairment were evaluated. Comparable to earlier studies, a moderate relation between slow fluctuating BOLD signal, i.e. ALFF, and hypercapnia-assessed hemodynamic impairment was found. ALFF did not significantly differ in between patients and controls, and ALFF only demonstrated a moderate effect size to detect hemodynamic impairment. This contrasted with the large effect size seen using hypercapnia-based hemodynamic assessment methods. In addition, based on our analysis of BOLD signal change as a response to a progressively increasing hypercapnia stimulus we can argue that a hypercapnia stimulus at least 2 mmHg above baseline EtCO2 is necessary to evaluate hemodynamic impairment. Up to 31% of the variance in the ALFF spatial distribution could be explained by the HO-BOLD spatial distribution, which was regarded a proxy for baseline venous CBV. These findings confirm that a substantial amount of the information imbedded in the rsBOLD signal, and the HC-BOLD signal (53% of the spatial variation), is strongly weighted by the baseline cerebral venous blood volume (vCBV).

The basis for investigating rsBOLD as a means to evaluate cerebral hemodynamics was established when rsBOLD signals were shown to have a relationship with EtCO2 (Wise et al., 2004; Chang and Glover, 2009). This finding lead to the presumption that breathing-related changes in arterial CO2 concentration pose small vasodilatory challenges, which result in concomitant changes in arterial CBV. However, this relation was attenuated in occlusion patients (from an R2 of 0.61 in controls to 0.33 in patients). The lower agreement found in our patient data as compared to the data of Liu et al. derived from patients with cerebrovascular disease may have been caused by differences in investigated BOLD frequency ranges (Liu et al., 2017a). In our data, we did not detect any significant differences in (f)ALFF between occlusion patients and controls, and this was reflected in a moderate effect size (0.61 for ALFF and 0.72 for fALFF) of rsBOLD MRI to detect hemodynamic impairment.

Compared with the rsBOLD data, the effect size for HC-BOLD was substantially higher compared to the rsBOLD results. Our results regarding the BOLD response to progressive hypercapnia may help to explain this finding. In this analysis, significant differences in the GM response were found only when the CO2 stimulus reached 2 mmHg above resting values. Breathing related fluctuations in EtCO2 values during
resting state measurements typically remain within 2 mmHg. Furthermore, it is known that the BOLD response to CO₂ follows a sigmoidal shape comprising a linear component about the resting vascular tone (Bhogal et al., 2014, 2015). Resting-state BOLD fluctuations are likely still around the linear regime of the response curve while HC-BOLD measurements integrate over the sigmoidal response curve and are thus more likely to detect mild to moderate hemodynamic impairment. Hence, it stands to reason whether basal EtCO₂ fluctuations are strong enough to act as a potent vascular stress stimulus and have a large enough effect size for detecting hemodynamic impairment, desirably already in a mild form. Besides the difficulties of rsBOLD MRI to detect hemodynamic impairment, we also demonstrated that a substantial amount of information imbedded in the ALFF was caused by baseline venous CBV (53% in case of healthy controls). After normalizing the ALFF by total amplitude across all frequencies (i.e. fALFF), purportedly to reduce large vessel contributions (Zou et al., 2008), vCBV still explained 29% of the variation in healthy controls. Therefore, care should be taken when attributing BOLD signal fluctuations such as (f)ALFF as a proxy for CO₂ vessel reactivity, especially in disease cases where cerebral blood volume can be compromised. As well, the reader should be aware that even though the set-up of a rsBOLD MRI sequence is less demanding, data-analysis is not straightforward yet and thus not readily applicable in clinical practice.

Findings from the rsBOLD analysis were also compared to time delay analysis and to the BOLD signal as a response to a progressively increasing hypercapnia stimulus. In line with the results reported by Donahue et al. (2015), our time delay analysis demonstrated a lower kurtosis and higher variance in patients with cerebrovascular disease (Donahue et al., 2015) with an effect size of 1.28 for time delay kurtosis and 1.56 for time delay variance. The effect size of the BOLD response to a progressively increasing hypercapnia stimulus (0.9) was large and a significant difference in GM response between occlusion patients and controls was found at +2 mmHg EtCO₂. This suggests that a shorter and less intense stimulus may be applied which would reduce scan time and possibly increase subject tolerance. Furthermore, this approach would eliminate the abrupt CO₂ increases associated with block hypercapnic stimuli which are thought to lead to a mixture of potentially confounding dynamic and static blood flow effects (Poublanc et al., 2015). An additional advantage of the BOLD response to a progressively increasing hypercapnia stimulus in GM (left panel) and WM (right panel) in controls (blue) and individuals with carotid artery occlusions (red). Global reductions in HC-BOLD are observed in individuals with occlusions. Inset top-right shows derivative curves of the HC-BOLD response. The HC-BOLD response in GM was significantly different starting from 2 mmHg above baseline EtCO₂. The WM HC-BOLD response showed no significant differences between patients and controls throughout the range of CO₂ values sampled (F(1, 18) = 2.67, p = 0.077). * denotes the ΔEtCO₂ values that showed significant differences in %BOLD between healthy controls and occlusion patients after post-hoc pairwise comparisons, Bonferroni adjusted. Mixed design analysis (ANOVA) demonstrated a significant interaction between group type (patients and healthy controls) and ΔEtCO₂ (F(1.74, 162) = 3.61, p = 0.045), indicating that the difference in %BOLD between occlusion patients and healthy controls depends on the level of administered EtCO₂.

Fig. 7. The HC-BOLD response to progressive hypercapnia in GM (left panel) and WM (right panel) in controls (blue) and individuals with carotid artery occlusions (red). Global reductions in HC-BOLD are observed in individuals with occlusions. Inset top-right shows derivative curves of the HC-BOLD response. The HC-BOLD response in GM was significantly different starting from 2 mmHg above baseline EtCO₂. The WM HC-BOLD response showed no significant differences between patients and controls throughout the range of CO₂ values sampled (F(1, 18) = 2.67, p = 0.077). * denotes the ΔEtCO₂ values that showed significant differences in %BOLD between healthy controls and occlusion patients after post-hoc pairwise comparisons, Bonferroni adjusted. Mixed design analysis (ANOVA) demonstrated a significant interaction between group type (patients and healthy controls) and ΔEtCO₂ (F(1.74, 162) = 3.61, p = 0.045), indicating that the difference in %BOLD between occlusion patients and healthy controls depends on the level of administered EtCO₂.
hypercapnia stimulus is that it could determine the precise onset, and thus, the severity of the vascular impairment where HC-BOLD will be insensitive to this information. Furthermore, we did not observe a significant difference between patients and controls for the HC-BOLD response to progressive hypercapnia in white matter. However, considering a p-value of 0.077 and given the fact that we used a dual-echo sequence which was not optimized for sensitivity to BOLD signal changes in white matter, there remains room for optimization in future MRI studies seeking to characterize white matter BOLD signal responses.

The findings described in this study have relevance with regard to the investigation of hemodynamic impairment in cerebrovascular disease, particularly the assessment of effect sizes. Effect sizes can be used to quantify and compare the strength of observed differences between two groups; in this case, occlusion patients and healthy controls (Sawilowsky, 2009). This information can be considered when designing clinical studies (power calculation and sample size planning) and when performing meta-analyses. However, when interpreting effect sizes a few limitations of the study should be considered. First, BOLD data gathered during respiratory modulation was used to obtain BOLD baseline signal changes in the baseline periods. Future studies could acquire resting-state BOLD MRI that employs longer baseline periods, and multi-slice and multi-echo acquisitions for higher temporal resolution and contrast-to-noise ratio. This may lead to larger effect sizes for ALFF and derived measures. Second, we focused on BOLD baseline signal changes within a frequency range of 0.01–0.08 Hz while Liu et al. have shown that the frequency range of 0.02–0.04 has the best relationship with EtCO2. Additional analyses (see supplemental Table 1) on the narrower frequency range did not show any notable differences in R (Blaser et al., 2002) values related to the comparison between (f)ALFF and HC/HO-BOLD. However, we did note slightly smaller effect sizes for (f) ALFF with the narrow range which may be attributed to the reduced signal-to-noise ratio when narrowing the frequency range. With our approach, we did find a similar relationship between rsBOLD MRI and HC-BOLD for controls as Liu et al., but, not in the occlusion patients. Third, we derived vCBV from HO-BOLD and this measure may have been confounded by the disease state of our subjects (i.e. collateral circulation in patients with carotid occlusion). A more suitable measure for vCBV could be achieved with dynamic susceptibility contrast (DSC) MRI (Kuppusamy et al., 1996) or vascular space occupancy (VASO) MRI (Li et al., 2003), although those techniques also have their limitations. For instance, DSC-derived CBV maps may be confounded by the arterial input function while quantitative VASO-based techniques may suffer from partial volume effects and differences in arterial arrival time which have to be properly corrected for using additional scans (Donahue et al., 2010; Hua et al., 2018).

Conclusion

Comparison of different BOLD-based hemodynamic assessment methods in patients with cerebrovascular disease and healthy controls demonstrated very large to very large effect sizes for hypercapnia-based methods (conventional HC-BOLD, time delay analysis and the BOLD response to an increasing hypercapnic stimulus) to detect hemodynamic impairment. Progressively increasing HC has the advantage of providing secondary CVR information not available when solely applying a boxcar-type HC stimulus. In this case, it allowed us to estimate the minimum stimulus necessary to distinguish hemodynamic-impaired subjects from controls. A hypercapnia stimulus of at least 2 mmHg above baseline EtCO2 was found to be necessary to depict hemodynamic impairment. Non-HC-based methods such as ALFF or fALFF only show moderate effect sizes and mainly seem to be confounded by resting CBV even though this must be confirmed in further studies. Our results indicate that vasoactive challenges are necessary to obtain reliable assessment of the brain’s hemodynamic status.

Acknowledgements

The research of Jeroen Hendriks has received funding from the European Research Council under the European Union’s Horizon 2020 Programme (H2020) / ERC grant agreement n°657024 (HEART-OFSTROKE) and H2020 grant agreement No 666881, SVDs@target. We would like to thank Blaise de B Frederick for sharing and his assistance on the time delay RapidTiDe code.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.neuroimage.2018.06.017.

References

Bhogal, A.A., Siero, J.C.W., Fisher, J.A., et al., 2014. Investigating the non-linearity of the BOLD cerebrovascular reactivity response to targeted hypercapnia at 7T. Neuroimage 98, 296–305.
Bhogal, A.A., Philippens, M.E.P., Siero, J.C.W., et al., 2015. Examining the regional and cerebral depth-dependent BOLD cerebrovascular reactivity response at 7T. Neuroimage 114, 239–248.
Bhogal, A.A., De Vis, J.B., Siero, J.C.W., et al., 2016. The BOLD cerebrovascular reactivity response to progressive hypercapnia in young and elderly. Neuroimage 139, 94–102.
Blaser, B.B., Kannurpatti, S.S., 2009. Resting-state functional connectivity in animal models: modulations by exsanguination. Meth. Mol. Biol. 255, 255–274.
Blaser, B., Yetkin, F.Z., Haughton, V.M., et al., 1995. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn. Reson. Med. 34, 537–541.
Blaser, B.B., Kannurpatti, S.S., Ryypma, B., 2007. Hemodynamic scaling of MRI-BOLD signal: validation of low-frequency spectral amplitude as a scalability factor. Magn. Reson. Imaging 25, 1558–1569.
Blaser, T., Hofmann, K., Buergger, T., et al., 2002. Risk of stroke, transient ischemic attack, and vessel occlusion before endarterectomy in patients with symptomatic severe carotid stenosis. Stroke 33, 1057–1062.
Bulte, D., Chiarelli, P., Wise, R., et al., 2007. Measurement of cerebral blood volume in humans using hyperoxic MRI contrast. J. Magn. Reson. Imag. 26, 894–899.
Champagne, A.A., Bhogal, A.A., Coverdale, N.S., et al., 2017. A novel perspective to calibrate temporal delays in cerebrovascular reactivity using hypercapnic and hypoxic respiratory challenges. Neuroimage. https://doi.org/10.1016/j.neuroimage.2017.11.044. Epub ahead of print 5 December.
Chang, C., Glover, G.H., 2009. Relationship between respiration, end-tidal CO2 and BOLD signals in resting-state fMRI. Neuroimage 47, 1381–1393.
Christen, T., Jabanian, H., Ni, W.W., et al., 2015. Noncontrast mapping of arterial delay and functional connectivity using resting-state functional MRI: a study in Moyamoya patients. J. Magn. Reson. Imag. 41, 424–430.
Christen, T., Jabanian, H., Ni, W.W., et al., 2015. Noncontrast mapping of arterial delay and functional connectivity using resting-state functional MRI: a study in Moyamoya patients. J. Magn. Reson. Imag. 41, 424–430.
Cogswell, P.M., Davis, T.L., Srother, M.K., et al., 2017. Impact of vessel wall lesions and vascular stenoses on cerebrovascular reactivity in patients with intracranial stenotic disease. J. Magn. Reson. Imag. 46, 1167–1176.
Conijn, M.M.A., Hoogduin, J.M., van der Graaf, Y., et al., 2012. Microbleeds, lacunar infarcts, white matter lesions and cerebrovascular reactivity — a 7T study. Neuroimage 59, 950–956.

Table 3

| Effect size | HC-BOLD (%) | HC-BOLD (z-value) | HO-BOLD (%) | HO-BOLD (z-value) | ALFF | fALFF | time delay kurtosis | time delay variance | HC-BOLD ramp |
|------------|-------------|------------------|-------------|------------------|------|-------|-------------------|-------------------|-------------|
| Cohen’s d  | 1.62        | 1.11             | 0.22        | 0.36             | 0.61 | 0.73  | 1.28              | 1.56              | 0.90        |

Effect sizes computed as the Cohen’s d to quantify and compare the strength of the observed differences between occlusion patients and healthy controls in terms of HC-BOLD (%BOLD and z-value), HO-BOLD (%BOLD and z-value), ALFF, fALFF, time delay kurtosis and variance measures, and CVR response to a progressive increase in EtCO2 (HC-BOLD ramp). Values below 0.5 are considered a small effect size, values above 0.8 and 1.2 are considered a large and very large effect size respectively (Sawilowsky, 2009).
